What Is The Estimated Seroconversion Rate Of Dengue Virus Serotype 2 (DENV-2) In The Context Of A Concurrent Zika Virus Outbreak, Given The Presence Of Pre-existing Flavivirus Immunity In A Population With High Aedes Aegypti Infestation Rates, And How Might This Impact The Interpretation Of IgM ELISA Results In A Prospective Cohort Study?
The estimated seroconversion rate of DENV-2 during a concurrent Zika outbreak, in a population with pre-existing flavivirus immunity and high Aedes aegypti infestation, is influenced by several factors:
-
Pre-existing Immunity and Cross-Reactivity: Previous exposure to flaviviruses can lead to cross-reactivity in antibody tests, potentially causing false positives or underestimating true seroconversion rates. This cross-reactivity might suppress the IgM response, complicating the detection of recent DENV-2 infections.
-
High Aedes Infestation: Increased mosquito populations elevate the risk of co-infections or sequential infections, which could affect the immune response and seroconversion dynamics.
-
Impact on IgM ELISA Results: The specificity of IgM ELISA tests is crucial. In areas with high flavivirus circulation, cross-reactivity may lead to either overestimation or underestimation of seroconversion rates, depending on the test's specificity and the population's prior immunity.
-
Prospective Cohort Study Considerations: Interpretation of results may be challenging due to potential biases from cross-reactivity and varied immunity. More specific tests or adjusted analytical methods might be necessary to account for these factors.
In conclusion, while the exact seroconversion rate is challenging to determine without specific data, it is likely influenced by pre-existing immunity and test specificity. The study's interpretation should consider these factors to ensure accurate results.